Introduction {#sec1}
============

New therapeutic strategies are needed if we are to better face the challenges posed by cancer, resistance to antibiotics, and viral infections. The development of systems that allow drugs to be more precisely delivered to their target organs, and that better control their release, is a major goal ([@ref211]; [@ref89]); non-specific drug delivery can be associated with toxic side effects in non-target tissues and organs.

It has been proposed that live bacteria be used as vectors for the *in situ* delivery of recombinant proteins for prophylactic and therapeutic purposes ([@ref140]; [@ref212]; [@ref30]; [@ref89]; [@ref46]). This strategy should be inexpensive since bacteria are easy to grow, the pharmaceutical production and purification of the active agent are avoided, and degradation problems (which are particularly severe in the gastrointestinal tract \[GIT\]) can be overcome ([@ref211]; [@ref206]). The producing bacteria can also be lyophilized, avoiding the need to maintain a cold chain ([@ref158]). Attenuated pathogenic bacteria were originally proposed for use in such systems, but lactic acid bacteria (LAB) quickly became recognized as ideal candidates, especially for the prevention and treatment of mucosal diseases ([@ref30]; [@ref206]).

Advantages of Lab as Live Vectors for the *In Situ* Production of Therapeutic Proteins {#sec2}
======================================================================================

The LAB form a heterogeneous group of Gram-positive bacteria that include technologically important species of the genera *Lactobacillus*, *Lactococcus*, *Streptococcus, Leuconostoc*, *Oenococcus*, and *Pediococcus*. They are mainly characterized by their ability to produce lactic acid from sugar -- an ability long exploited by humans to produce fermented foods such as cheese, yoghurt, sausage, wine, sauerkraut, and pickled vegetables. Such foods can be safely consumed long after they are made and may even be of enhanced nutritional value. The presence of LAB in foods and their lack of pathogenic traits or association with any foodborne disease have led to their being regarded as safe. In fact, most LAB species are 'generally regarded as safe' (GRAS) by the US Food and Drug Administration (FDA) and have been awarded 'qualified presumption of safety' (QPS) status by the European Food Safety Authority (EFSA).

LAB occupy a wide range of niches. Some species are found in milk and in plants, while others are common members of the endogenous microbiota associated with the oral, urogenital, and GIT mucosae in animals and humans ([@ref101]). Certain LAB strains play a role in controlling the intestinal microbiota, restoring the intestinal barrier function, and alleviating the inflammatory responses associated with GIT disease. This has fomented their use in the treatment and prevention of various intestinal disorders ([@ref157]; [@ref96]; [@ref64]). Certain LAB groups, such as the lactobacilli, are important members of the endogenous microbiota of human mucosal surfaces, where they play crucial roles in homeostasis, providing the protection against pathogenic bacteria and stimulating the immune system ([@ref96]; [@ref25]). Given their beneficial nature, LAB species such as *Lactobacillus acidophilus*, *Lactobacillus casei*, and *Lactobacillus rhamnosus*, which meet the definition of probiotics ([@ref55]), have been added to food to provide consumers with their health benefits ([@ref172]; [@ref64]; [@ref170]). Indeed, LAB, and lactobacilli in particular, have become a focus of interest for use in human and animal biomedical applications ([@ref212]; [@ref21]; [@ref30]; [@ref206]).

LAB are reported to be ideal candidates as live delivery vehicles for releasing therapeutic and prophylactic molecules directly at the oral, nasal, and genital mucosae and to be a realistic option for the treatment of human and animal diseases ([@ref30]; [@ref161]; [@ref206]). The safety status of the LAB, the ability of some strains to survive passage through the GIT ([@ref203]), and the capacity of some species (e.g., *L. rhamnosus*, *Bifidobacterium animalis*, and *Lactobacillus plantarum*) to remain viable in the GIT for a period of time render food-grade LAB ideal vehicles for delivering and even producing therapeutic molecules *in situ* at the GIT mucosa ([@ref38]; [@ref206]). The absence of lipopolysaccharides (LPSs) in their cell walls (which is not the case in Gram-negative bacteria such as *Escherichia coli*) is a further advantage, allowing them to be administered orally without the risk of endotoxic shock ([@ref189]). In addition, the oral administration of therapeutic molecules *via* live recombinant LAB is a suitable alternative to invasive administration methods, for example, parenteral or subcutaneous injection, avoiding their potential side effects. Further, it circumvents the degradation of orally administered naked molecules in the digestive tract and ensures the production of the therapeutic protein at the GIT mucosa ([@ref206]). Moreover, the *in vivo* synthesis of the therapeutic molecule reduces the dose required when compared to systemic or subcutaneous treatment ([@ref186]; [@ref30]).

In recent decades, much effort has gone into the genetic manipulation of LAB with the aim of producing recombinant therapeutic molecules ([@ref63]; [@ref30]). Tools that allow cloning, the modulation of expression, and even the localization of recombinant proteins are now available ([@ref40]; [@ref136], [@ref137]; [@ref79]; [@ref22]; [@ref120]; [@ref119]; [@ref143]). Recombinant proteins can be engineered to be secreted into the extracellular environment or to be secreted and then anchored on the bacterial surface. Proteins to be secreted must have an N-terminus signal peptide recognized by the bacterial secretion machinery. One of the secretion mechanisms most studied in genetic engineering is the Sec-dependent pathway ([@ref129]). This drives the translocation of the precursor protein (i.e., the signal peptide plus the mature protein) across the plasma membrane. Either during or after translocation, a signal peptidase cleaves off the signal peptide and the mature protein is released into the extracellular environment ([@ref174]). Different signal peptides have been exploited for engineered secretion in LAB, such as that associated with the major lactococcal secreted protein Usp45 ([@ref45]), the *Lactobacillus brevis* S-layer protein (SlpA) ([@ref152]), the *Streptococcus pyogenes* M6 protein ([@ref86]), and the *Lactobacillus crispatus* aggregation-promoting factor (APF) ([@ref137]; [@ref159]; [@ref76]), among others ([@ref129]). Secreted recombinant proteins can also be engineered by the translational fusion of an anchor peptide (displayed on the bacterial surface) *via* covalent or non-covalent bonding ([@ref44]; [@ref222]; [@ref130]; [@ref143]). Indeed, several anchoring peptides derived from surface-exposed proteins of Gram-positive bacteria have been used to bind secreted recombinant proteins to the surface of LAB -- either to the plasma membrane or to the cell wall components ([@ref143]). The signals used to anchor the protein to the cell membrane include N-terminal transmembrane helix anchors, for example, the transmembrane domain of the PgsA protein from *Bacillus subtilis* ([@ref150]), and lipoprotein anchor domains, for example, the anchor domain of lactococcal basic membrane protein A (BmpA) ([@ref223]). Recombinant proteins can be covalently anchored to the bacterial cell wall, which is usually achieved by fusing the target protein to an LPXTG-type cell wall-sorting signal. This consists of an LPXTG motif followed by a C-terminal hydrophobic domain and a positively charged tail that adequately orientates the protein in the membrane, allowing a membrane-anchored sortase to cut a peptide bond of the LPXTG motif and catalyze covalent bonding with the peptidoglycan ([@ref173]; [@ref178]). The LPXTG anchors used include the cell-wall anchor of the *S. pyogenes* M6 protein ([@ref45]; [@ref35]), the anchor sequence of proteinase P of *Lactobacillus zeae* ([@ref105]; [@ref137]), and the LPXTG anchor of the cell wall surface adherent protein Lp_2578 produced by *L. plantarum* WCFS1 ([@ref59]). Recombinant proteins may also be non-covalently attached to the cell wall of LAB by fusing them to different cell wall-binding domains such as the anchoring system of the APF of *L. crispatus* ([@ref137]), the lysin motif (LysM) ([@ref58]), and the C-terminal region of S-layer proteins ([@ref90]). Thanks to these genetic tools, a large number of recombinant LAB strains have been designed that produce therapeutic or prophylactic proteins ([@ref212]; [@ref23]; [@ref38]; [@ref30]; [@ref206]).

Recombinant Lab that Produce Therapeutic Molecules {#sec3}
==================================================

Some LAB are natural components of the GIT microbiota. Strains such as *L. rhamnosus* GG and *B. animalis* BB12 have been used as probiotics for modulating the GIT microbiota and even to treat some intestinal disorders ([@ref65]). The earliest use of therapeutic molecule-producing recombinant LAB was in the treatment of GIT inflammatory diseases and bacterial and viral infections. The literature now contains many articles describing LAB genetically engineered to produce therapeutic proteins for use in the treatment of gastrointestinal disease ([@ref23]; [@ref30]; [@ref138]).

Recombinant LAB for Use Against GIT Inflammatory Diseases {#sec4}
---------------------------------------------------------

Many recombinant LAB have been developed to fight inflammatory bowel disease (IBD), a group of disorders that cause chronic inflammation in different parts of the GIT. Crohn's disease and ulcerative colitis are the two most important types. Almost two decades ago, a recombinant strain of *Lactococcus lactis* was engineered to secrete the anti-inflammatory interleukin 10 (IL-10) ([@ref186]), and when administered orally, it reduced colitis in two mouse models (mice treated with dextran sulfate sodium \[DDS\] and IL-10^−/−^ mice). The success obtained led the authors to continue their research with the aim of performing clinical trials, and they developed a biocontained *L. lactis* producing IL-10 in which the host thymidylate synthase gene (*thyA*) was replaced by a synthetic human *IL-10* gene. Since *thyA* is essential for the growth of *L. lactis*, the viability of the biocontained strain depended on the presence of thymidine or thymine ([@ref187]). A Phase I clinical trial involving patients with Crohn's disease reported reduced disease activity and confirmed the strain's biocontainment, safety, and tolerability ([@ref28]).

Other recombinant LAB strains designed for the oral delivery of anti-inflammatory molecules to the gut have also been reported to prevent or reduce inflammation in different murine models of colitis ([@ref30]; [@ref206]). For example, *L. lactis* strains were engineered to produce the immunomodulatory low calcium response V (LcrV) protein of *Yersinia pseudotuberculosis* ([@ref57]), the cytoprotective trefoil factor (TFF) ([@ref199]), the immunosuppressive cytokine interleukin 27 (IL-27) ([@ref80]), insulin-like growth factor I (IGF-I) ([@ref124]), heat shock protein 65 (Hsp65) ([@ref71]), and serine protease inhibitors ([@ref24]). Recombinant *L. casei* producing superoxide dismutase has also been designed ([@ref208]).

Celiac disease, an autoimmune disorder of genetically pre-disposed individuals, also causes bowel inflammation after the ingestion of gluten. The oral administration of live recombinant LAB producing prolyl endopeptidases -- enzymes that degrade the immunotoxic peptides of gluten -- might be a way of preventing an inflammatory response ([@ref9]). A generated food-grade recombinant *L. casei* strain was reported to stably and constitutively secrete a prolyl endopeptidase able to break down the 33-mer peptide of gluten (one of the most immunotoxic). The strain also resisted deactivation under simulated gastrointestinal conditions in an *in vitro* model with its ability to secrete the enzyme intact ([@ref9]).

Recombinant LAB as Live Mucosal Vaccines {#sec5}
----------------------------------------

One of the most extended uses of recombinant LAB that produce therapeutic or prophylactic molecules is as live mucosal vaccines ([@ref212]; [@ref215]; [@ref189]). In addition to the already mentioned advantages of LAB as live mucosal delivery vehicles, these microorganisms have additional properties that render them good choices as live vaccine vectors for mucosal vaccination. For instance, some LAB strains show innate immunoadjuvant properties that enhance the immune response provoked by the desired heterologous immunogenic molecule ([@ref79]; [@ref144]; [@ref23]). In addition, they have the potential to elicit antigen-specific cellular, mucosal, and systemic humoral immune responses ([@ref41] [@ref42]; [@ref212]; [@ref23]). Further, live recombinant LAB allow for immunization *via* the oral route, enabling the production *in vivo* of the therapeutic or prophylactic molecules at the GIT mucosa and avoiding the degradation of the treatment molecule in the harsh environment of the stomach ([@ref206]). Moreover, administration is non-invasive and can be performed by personnel with relatively low-level training. There are neither any needles nor syringes to dispose of. It is therefore an ideal strategy for large-scale immunization programs ([@ref43]). Finally, the possibility of storing recombinant lyophilized LAB avoids the need for a cold chain, making these types of vaccine suitable for use in developing countries.

### LAB for Active Immunization {#sec6}

Recombinant LAB that produce microbial antigens have been proposed as oral vaccines against a range of pathogens. Back in 1993, *L. lactis* was engineered to express fragment C of the tetanus toxin (TTFC) ([@ref227]). Further studies showed that the administration of TTFC-expressing recombinant *L. lactis via* either the nasal ([@ref151]) or the oral route ([@ref166]) protected mice against a lethal challenge with tetanus toxin. Since then, a large number of recombinant LAB strains have been generated as potential mucosal vaccines to prevent infections caused by other pathogens ([@ref211]; [@ref206]). Several recombinant LAB orally administered in appropriate animal models were reported to confer *in vivo* protection against infections of the GIT caused by *Helicobacter pylori* ([@ref74]; [@ref87]; [@ref115]), enterohemorrhagic *Escherichia coli* (EHEC) ([@ref3]), enterotoxigenic *E. coli* (ETEC) ([@ref123]; [@ref209]; [@ref213]), *Clostridium difficile* ([@ref217]; [@ref77]), *Salmonella enterica* ([@ref98]), rotavirus ([@ref134]), the yeast *Candida albicans* ([@ref176]), and even parasites such as *Plasmodium yoelii* ([@ref225]) and *Giardia lamblia* ([@ref113]). Peptide allergen-producing LAB have also been proposed as a therapeutic option for the treatment of peanut ([@ref162]) and cow's milk allergies ([@ref2]).

### LAB for Passive Immunization {#sec7}

LAB might also be used to produce antibodies to generate passive immunity. Passive immunity, which involves the transfer of ready-to-act antibodies, occurs naturally when maternal antibodies are transferred to the fetus through the placenta, and during lactation. However, it can be artificially induced by transferring large numbers of pathogen- or toxin-specific antibodies to a non-immune individual through blood products, for example, in immunoglobulin or antiserum therapy. LAB can be used as a vehicle for passive immunization by engineering them to produce specific antibodies. LAB producing single-chain variable fragment (scFv) antibodies (chimeric molecules that fuse two different regions of both heavy and light immunoglobulin chains) ([@ref81]) have been developed in an attempt to provide passive protection against different diseases of the GIT and other organs ([@ref177]; [@ref68]; [@ref145]; [@ref31]; [@ref133]; [@ref220]; [@ref211]; [@ref190]; [@ref142]; [@ref132]; [@ref206]). After being orally administered in the corresponding animal model, passive immunoprotection developed against gastrointestinal infections caused by *C. albicans* ([@ref154]), *Streptococcus mutans* ([@ref105], [@ref107]), norovirus ([@ref85]), and against anthrax edema toxin ([@ref11]).

VHH Antibody Fragments {#sec8}
======================

In addition to conventional immunoglobulin G (IgG) antibodies, the serum of llamas, camels, and dromedaries has antibodies with two identical heavy chains but no light chains ([@ref78]; [@ref147]). The variable domains of these heavy chains are recognized as a new class of antibody fragment: VHH antibody fragments (also known as nanobodies or single-domain antibodies \[sdAbs\]; hereafter referred to simply as VHH). These have many advantages over conventional monoclonal antibodies (mAb) and scFv, which has encouraged research into their use possible clinical agents, either in purified form or delivered by VHH-producing live systems.

Advantages of VHH Over Conventional Antibodies {#sec9}
----------------------------------------------

Despite their small size -- 12--15 kDa compared to the 150 kDa of traditional antibodies -- VHH can recognize and bind to haptens, oligopeptides, and proteins. Indeed, they are the smallest fragments that retain the full antigen-binding capacity of antibodies. Their small size and structural properties allow them to behave like drugs and invest them with unique advantages over mAb for use in biotechnological and biomedical applications ([@ref81]; [@ref70]; [@ref53]). For example, VHH are of low immunogenicity because of their notable sequence similarity with the VHIII subset family of human VH ([@ref37]; [@ref188]; [@ref19]). They also show good solubility and little tendency to aggregate due to the presence of polar and charged amino acid residues ([@ref181]); they exhibit potent-binding capacity ([@ref148]) and have a high affinity for their antigens ([@ref148]). VHH antibody fragments also show remarkably high-conformational stability and can fully reverse the unfolding process induced by denaturing agents and conditions (such as those encountered in the stomach). They can also resist high pressures and urea and guanidinium chloride concentrations ([@ref51]), are extremely stable at high temperatures (below 50 to over 80°C) ([@ref195]; [@ref51]), and remain functional under low pH conditions (as low as pH 2) ([@ref196]). Protein engineering has improved the refolding capacity of VHH and therefore their stability under such denaturing conditions ([@ref70]).

In addition to the conformational stability of VHH, the paratope of these antibody fragments (i.e., the region of the antibody that binds to an epitope) occupies such a small part of the antibody that the recognition of hidden regions of epitopes, hardly accessible to mAb, becomes possible ([@ref148]). Further, and in contrast to mAb, VHH can act as potent and specific enzyme inhibitors since they can access protein cavities and bind to the active site ([@ref110]). Moreover, VHH penetrate tissues much better than mAb and can therefore target solid tumors and metastatic lesions much more effectively ([@ref37]).

The single-domain nature of VHH allows for the easy cloning of VHH-encoding genes, as well as the generation of multimeric VHH using the same or different building blocks. Multivalent VHH are created when two or more identical target-binding VHH are combined. In addition, multiparatopic or multispecific VHH can be created by combining different VHH targeting different antigens or different epitopes of the same antigen ([@ref54]; [@ref81]; [@ref93]). Increasing the valency and specificity of VHH enhances their therapeutic efficacy, potency, and cross reactivity over that of monovalent and monospecific VHH ([@ref93]; [@ref92]).

These beneficial properties of VHH have boosted their use in the detection of toxins in foods ([@ref216]; [@ref205]), in disease diagnosis ([@ref39]; [@ref91]; [@ref114]), in pathogen detection ([@ref168]; [@ref1]), and in the treatment of different diseases in humans ([@ref91]) and animals ([@ref82]; [@ref122]). The following lines focus on their use in the treatment of non-infectious and infectious diseases of the human GIT.

VHH as Immunotherapeutic Agents Against Diseases of the GIT {#sec10}
-----------------------------------------------------------

VHH have been used to combat GIT inflammatory diseases, infections, and cancers ([@ref185]).

### VHH Against Gastrointestinal Inflammatory Diseases {#sec11}

Over the last decade, interest has increased in developing VHH antibodies that target proteins involved in inflammation as a means of treating gastrointestinal inflammatory diseases, including IBD ([@ref185]). [@ref29] generated a biparatopic VHH against the chemokine receptor CXCR2, a G-protein-coupled receptor that plays an important role in mediating the chemotaxis of neutrophils to sites of inflammation, which is involved in a variety of acute and chronic inflammatory diseases, including IBD, asthma, fibrosis, psoriasis, and rheumatoid arthritis ([@ref184]). This recognized two different epitopes, allowing it to act as an inverse agonist and inhibitor of CXCR2 signaling *in vitro* -- a promising strategy for treating inflammatory diseases.

### VHH Against Gastrointestinal Bacterial and Viral Infections {#sec12}

VHH have also been directed against bacterial pathogens and their toxins. The intensive clinical and agricultural use of antibiotics has favored the emergence of multi-resistant pathogens that cause difficult-to-treat or even un-treatable healthcare-associated and community-acquired infections ([@ref207]; [@ref60]). There is therefore an urgent need to develop non-antibiotic antimicrobial agents to combat these pathogens. VHH have been designed to target different bacterial pathogens of the gut (or their toxins) ([@ref185]), for example, against *S. mutans*, the main cause of dental caries ([@ref149]). The oral administration of VHH targeting streptococcal antigen I/II (SA I/II), a cell wall-anchored adhesin present on the bacterial surface, reduced the development of smooth surface caries in a rat-desalivated caries model, probably by blocking the binding of the bacteria to the enamel pellicle ([@ref106]). VHH have also been developed against *Campylobacter jejuni*, a zoonotic pathogen that causes foodborne gastroenteritis worldwide ([@ref97]). An orally administered pentameric VHH directed against the flagella of this pathogen (a major virulence factor) reduced its motility *in vitro* and significantly reduced colonization in infected chickens ([@ref163]). VHH have also been raised against *H. pylori*, a common pathogen that causes gastritis, gastric and duodenal ulcers, gastric cancer, and other gastrointestinal diseases ([@ref202]). Some VHH target an important virulence factor, in this case the pathogen's urease enzyme ([@ref13]; [@ref88]). This hydrolyses urea into ammonia, helping to neutralize the gastric acid in the bacteria's environment and aiding their colonization of the epithelium ([@ref135]; [@ref156]). These neutralizing VHH were resistant to pepsin and trypsin, an important trait for any VHH to be used in the treatment of *H. pylori* infection.

Other VHH antibodies have also been generated to target the botulinum neurotoxins of *Clostridium botulinum* ([@ref48]; [@ref146]; [@ref17]; [@ref219]), the shiga toxins produced by shiga toxin-producing *E. coli* strains (STEC) ([@ref192]; [@ref141]), and toxin A (TcdA), toxin B (TcdB), and binary toxin (CDT) of *C. difficile* ([@ref94]; [@ref218]; [@ref194]).

VHH have also shown a promise against human viral diseases ([@ref200]; [@ref214]). Some have been designed to block the entry of viruses into the host cells by targeting the viral envelope proteins, while others target essential intracellular viral proteins ([@ref214]). These agents have shown a particular promise against rotavirus and norovirus ([@ref67]), the most common causes of severe acute gastroenteritis in children ([@ref165]). Several VHH generated against Group A rotavirus (RVA) strains were shown to neutralize rotavirus *in vitro* and provided different degrees of *in vivo* passive protection against rotavirus challenge when orally administered in a neonatal mouse model ([@ref196]; [@ref62]; [@ref72]; [@ref191]; [@ref127]). They also provided protection against human RVA-induced diarrhea in gnotobiotic piglets ([@ref201]). The therapeutic efficacy of an anti-rotavirus VHH known as ARP1 (ARP: anti-rotavirus protein) has been demonstrated in a randomized placebo-controlled clinical trial ([Clinicaltrials.gov](http://Clinicaltrials.gov) number: NCT01259765). The oral administration of purified ARP1 to children with severe rotavirus-associated diarrhea reduced the stool output ([@ref171]). VHH have also been raised against the two major norovirus genogroups (GI and GII) ([@ref61]; [@ref103] [@ref104]), with some showing promise in *in vitro* surrogate neutralization assays ([@ref61]). Anti-rotavirus and anti-norovirus VHH would therefore appear to have a great potential as immunotherapeutic agents in infections caused by these pathogens.

### VHH as Anti-Tumoral Agents {#sec13}

VHH are gaining importance as anti-tumoral agents. Their small size, tumor penetrating capacity, and homogeneous distribution compared to mAb can lead to improved treatment results, and even tumor eradication ([@ref18]). In addition, the discovery and production costs for VHH are lower than those associated with mAb, perhaps allowing for more affordable and sustainable cancer treatments. The absence in VHH of the fragment crystallizable (Fc) region of IgG, which is present in mAbs, might also reduce the adverse immune responses associated with this domain ([@ref185]). However, its absence might also reduce the efficacy of VHH in cancer treatment ([@ref185]; [@ref91]) since it triggers the antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) reactions upon antigen binding; both are important in tumor eradication ([@ref210]). These findings have together boosted the search for VHH anti-tumoral agents ([@ref155]; [@ref100]; [@ref185]; [@ref91]; [@ref95]).

The growth of certain gastrointestinal tumors has already been reported to be reduced by some VHH ([@ref36]; [@ref167]). VHH have been designed to elicit the ADCC and CDC responses, such as a Fab-like bispecific antibody that comprised a VHH targeting the carcinoembryonic antigen (CEA; a well-characterized tumor marker of interest for mAb-based cancer therapy) and a VHH that specifically bound and activated the FcγRIIIa receptor (an Fc-receptor class with important anti-tumoral effects) ([@ref167]). This antibody triggered potent *in vitro* cell-mediated cytotoxicity toward different CEA-positive human tumor cell lines (including human colon adenocarcinoma and primary pancreatic adenocarcinoma lines) in the presence of natural killer cells used as effector cells. Further, it showed potent *in vivo* activity, inhibiting tumor growth after being injected intraperitoneally together with human peripheral blood mononuclear cells in mice xenografted with a CEA-positive pancreatic cell line.

Other anti-tumoral VHH have been designed to block inhibitory immune checkpoints ([@ref224]). These are inhibitory pathways that under normal physiological conditions prevent autoimmunity and modulate immune response against microbial infections to prevent tissue damage ([@ref193]). Some inhibitory immune checkpoints are upregulated in many cancers as a mechanism of tumor resistance to, and evasion of, the host immune system ([@ref226]). Antibodies that block immunosuppressive checkpoints are therefore emerging as promising strategies ([@ref160]; [@ref108]; [@ref180]; [@ref175]). For example, immunotherapies based on the blockade of PD-1/PD-L1 (PD-1, or programmed death protein-1, is a surface cell receptor present in activated T-cells, and PD-L1, or ligand 1 of PD-1, is abundant in cells of colon cancer and other carcinomas) ([@ref47]; [@ref50]) using anti-PD-1 ([@ref121]; [@ref112], [@ref111]; [@ref153]) or anti-PD-L1 mAb ([@ref83]; [@ref180]) have led to remarkable clinical responses in patients with colorectal cancer. In the context of VHH, [@ref224] developed an intraperitoneally administered anti-PD-L1 nanobody fused to the Fc-domain of human IgG1 that efficiently inhibited the PD-1/PD-L1 interaction, induced the T-cell cytokine production *in vitro*, and caused the *in vivo* inhibition of tumor growth in a melanoma xenograft mouse model.

Another immunotherapeutic strategy aimed at impeding the growth of gastrointestinal and other tumors is the use of antibodies targeting angiogenic factors. Angiogenesis, a process whereby new blood vessels are formed from existing vessels, is over-induced in tumors. The new vessels that form in the vicinity of the tumor provide it with nutrients and oxygen ([@ref102]). VHH that block overproduced pro-angiogenic factors have been shown effective in preventing tumor angiogenesis and therefore offer a promise as anti-tumoral agents ([@ref14]). VHH have been developed that target key regulators of tumor angiogenesis, such as vascular endothelial growth factor (VEGF) ([@ref56]; [@ref52]; [@ref99]), placental growth factor (PLGF) ([@ref15]), and vascular endothelial growth factor receptor 2 (VEGFR-2) ([@ref20]; [@ref66]; [@ref126]), among others ([@ref14]). In addition, they have been directed against hepatocyte growth factor (HGF) and its receptor c-Met since HGF/c-Met-signaling is involved in angiogenesis and the progression of different gastrointestinal cancers, including colon and gastric cancers ([@ref27]; [@ref100]; [@ref14]). A VHH targeting HGF reduced the growth of solid tumors in mice bearing glioblastoma xenografts (interestingly, some mice were even cured) ([@ref204]), while an anti-c-Met VHH efficiently inhibited cell proliferation, adhesion, and *in vitro* migration in HGF-mediated multiple myeloma ([@ref182]). VHH that target angiogenic factors may therefore have a bright future as anti-tumoral/anti-metastatic immunotherapeutic agents.

Lab that Produce VHH {#sec14}
====================

The small size and the hydrophilic and single-domain nature of VHH allow for their easy production in different eukaryotic systems, including yeasts (e.g., *Saccharomyces cerevisiae* and *Pichia pastoris*), fungi (e.g., *Aspergillus awamori* and *Aspergillus oryzae*), plants (e.g., *Nicotiana benthamiana* and *Arabidopsis thaliana*), mammalian cell lines \[e.g., Chinese hamster ovary (CHO) cells and mouse B cells\], and insect cells (e.g., those of *Spodoptera frugiperda* and *Trichoplusia ni*). They can also be produced in prokaryotic microorganisms, including Gram-negative bacteria such as *E. coli*, Gram-positive bacteria such as *Brevibacillus choshinensis,* some species of LAB, and species belonging to the genus *Bifidobacterium* ([@ref81]; [@ref125]). The eukaryotic systems allow for the production of soluble, functional, and N-glycosylated VHH, although degradation by proteases and inefficient secretion can reduce the yield obtained. It should be remembered, however, that some of these systems, for example, mammalian cells, are quite expensive for use in large-scale production ([@ref125]). In addition, they cannot be used for the *in situ* delivery of the VHH produced. Prokaryotic systems are therefore preferable. These can be genetically manipulated with relative ease and are more economically viable as production systems. *E. coli* is one of the microbial hosts most widely used for VHH production ([@ref125]). However, it has some limitations. The reducing environment of its cytoplasm, for example, drives the incorrect folding of VHH and the formation of insoluble and non-functional aggregates ([@ref125]). In addition, the presence of LPS in the bacterial membrane -- which is pyrogenic in humans and other mammals ([@ref131]) -- limits its use as a host.

In contrast, Gram-positive bacteria, including the LAB, have no LPS in their cell membranes ([@ref128]). This, plus the other characteristics of LAB mentioned earlier, renders this group a better alternative when producing VHH for therapeutic use. This is particularly true when they are to be orally administered as live systems for delivering VHH to the GIT ([@ref158], [@ref159]; [@ref198]; [@ref137]; [@ref8]; [@ref12]).

*L. lactis* is one of LAB species of choice for such a delivery system. This non-pathogenic bacterium can be safely consumed; indeed, it has been used for centuries in food fermentation and preservation without raising any safety concerns, and it has been granted QPS status by the EFSA ([@ref164]) and GRAS status by the FDA ([@ref212]). In addition, it is a non-invasive, non-colonizing bacterium ([@ref186]), and many genetic engineering tools are available that can induce its production of a wide range of heterologous proteins ([@ref183]). These advantages make *L. lactis* a successful microbial cell factory and have prompted its use as a vehicle for delivering therapeutic molecules directly into the GIT ([@ref183]).

Other LAB -- specifically the members of the genus *Lactobacillus* -- have been engineered to produce VHH directly in the GIT. These have extra advantages as VHH delivery vehicles. In addition to being safe for consumption, many *Lactobacillus* strains are normal constituents of the human gut microbiota and can survive passage to the intestine since they are resistant to gastric and bile acids. They also transiently adhere to the mucosal epithelium and have intrinsic immunostimulatory properties ([@ref9]; [@ref43]). Moreover, some *Lactobacillus* strains have probiotic characteristics and are beneficial to health ([@ref16]). For instance, *L. rhamnosus* GG, *L. casei* Shirota YIT9029, and *L. casei* DN-114001, among others, have antimicrobial effects against gastric and enteric bacterial pathogens and rotavirus ([@ref116]). Moreover, many genetic engineering tools, such as plasmid-based cloning systems, are available to help generate recombinant *Lactobacillus* strains capable of producing heterologous proteins ([@ref109]). Other technologies conferring selective advantages over the use of plasmids are also available, such as genome editing for the stable integration of expression cassettes in the bacterial chromosome (based on the integrative machinery of bacteriophages) ([@ref136], [@ref137]; [@ref117]; [@ref9]), systems based on integration by double recombination ([@ref73]; [@ref187]; [@ref49]), and technologies based on clustered regularly interspaced short palindromic repeats (CRISPR) and associated (Cas) proteins (CRISPR/Cas) ([@ref84]; [@ref197]). *Lactobacillus* is currently regarded as the most suitable LAB genus for the oral delivery of VHH against diseases of the GIT. Indeed, *Lactobacillus paracasei* was the first LAB species engineered to produce VHH, which were termed as "lactobodies" ([@ref158]).

The following lines provide a comprehensive review of all the recombinant LAB that have been genetically engineered to deliver VHH antibodies *in situ* at the GIT mucosa.

LAB That Produce VHH Against Gastrointestinal Inflammatory Diseases {#sec15}
-------------------------------------------------------------------

Tumor necrosis factor alpha (TNFα) is one of the major cytokines involved in the pathogenesis of IBD ([@ref26]), and immunotherapy with anti-TNFα antibodies is becoming recognized as an efficient treatment ([@ref26]). [@ref198] developed recombinant *L. lactis* strains that secreted monovalent (MT1) and bivalent (MT1-MT1; constructed using two MT1 and a llama IgG2a upper hinge) ([@ref34]) VHH against murine TNFα (Figure [1](#fig1){ref-type="fig"}). Both the MT1 and (especially) the MT1-MT1 VHH neutralized the soluble and the transmembrane forms of TNFα *in vitro*. The same study revealed the *in vivo* therapeutic efficacy of orally administered recombinant *L. lactis* secreting MT1-MT1 in terms of reducing the symptoms of chronic colitis in two mouse models (DSS-induced colitis and established colitis in IL-10^−/−^ mice). Importantly, the study also showed that the production of MT1-MT1 at the site of inflammation avoided the increase in the incidence of systemic viral and bacterial infections sometimes observed after the intravenous administration of purified anti-TNFα IgG1 antibodies. This result is of great importance since current treatments for Crohn's disease and ulcerative colitis involve the intravenous administration of anti-TNFα IgG1 antibodies ([@ref33]; [@ref221]). The oral administration of anti-TNFα VHH-producing *L. lactis* provides a way of treating chronic GIT inflammation locally, avoiding the adverse effects associated with systemically administered anti-TNFα antibodies.

![Recombinant LAB that produce VHH against intestinal inflammatory bowel diseases. Recombinant *Lactococcus lactis* strains secreting either monovalent MT1 or bivalent MT1-MT1 VHH against TNFα, an inflammatory cytokine involved in inflammatory bowel disease. The gene encoding MT1 VHH is constitutively expressed within a replicative plasmid either as a single copy (monovalent form, MT1 VHH) or as two copies in tandem (bivalent form, MTI-MT1 VHH).](fmicb-09-03179-g001){#fig1}

LAB That Produce VHH Targeting Bacterial Toxins {#sec16}
-----------------------------------------------

Lactobacilli have been engineered to produce VHH to combat gastrointestinal infections caused by *C. difficile*, the leading cause of nosocomial infections in healthcare settings ([@ref5]), and of most antibiotic-associated diarrheal disease. It is also a causal agent of pseudomembranous colitis, megacolon, and chronic infections and can even cause death ([@ref4]). *C. difficile* produces two secreted enzymatic exotoxins TcdA and TcdB ([@ref5]); these are major virulence factors of this bacterium and are clearly responsible for associated diarrhea and colitis ([@ref32]). TcdA and TcdB exert their effects by binding to surface receptors on intestinal epithelial cells ([@ref5]).

[@ref12] proposed an oral antitoxin strategy for the prevention and treatment of *C. difficile*-associated diarrhea, based on the neutralization of TcdB using engineered *L. paracasei* BL23 that constitutively produced anti-TcdB VHH in the GIT (Figure [2](#fig2){ref-type="fig"}). These authors generated several recombinant *L. paracasei* strains that produced neutralizing anti-TcdB VHH that targeted different epitopes of the exotoxin. The bacteria were engineered to either secrete anti-TcdB VHH into the extracellular medium or produce them anchored to the cell wall. Both types neutralized TcdB *in vitro*. Importantly, the oral administration of a combination of two strains displaying different cell wall-anchored anti-TcdB VHH delayed the development of *C. difficile* infection and provided partial protection in a hamster protection model ([@ref12]). These results confirmed the prophylactic effect of such VHH against this pathogen. It should also be noted, however, that the oral administration of purified anti-TcdB VHH produced by a yeast provided no such protection *in vivo*, probably due to the proteolytic degradation of the antibodies under the harsh conditions of the GIT ([@ref198]). These results highlight the advantages of the continuous production of neutralizing VHH anchored to the cell wall and acting *in situ* in the GIT: this system avoids the degradation suffered by purified VHH and might prevent the diffusion of the toxin by sequestering it on the bacterial surface. Engineered lactobacilli producing surface-exposed anti-TcdB VHH might be used to complement existing therapies designed to tackle *C. difficile* infection.

![Recombinant LAB that produce VHH against the TcdB exotoxin of *Clostridium difficile.* Recombinant *Lactobacillus paracasei* strains producing four different VHH (G3, D8, B2, and E2) against the TcdB exotoxin of *Clostridium difficile*. Some of these strains secrete the VHH into the extracellular environment, while others produce it covalently attached to the cell wall. The VHH-encoding genes are constitutively expressed within replicative plasmids inside the *L. paracasei* cells.](fmicb-09-03179-g002){#fig2}

LAB That Produce VHH Against Viruses {#sec17}
------------------------------------

Most of the lactobacilli engineered to produce VHH have been developed to treat or provide protection against rotavirus infection (Figure [3](#fig3){ref-type="fig"}). [@ref158] proposed an oral prophylactic therapy to prevent rotavirus-associated diarrhea based on engineered *Lactobacillus* that produced anti-rotavirus VHH *in situ* in the GIT. This was the first time that lactobacilli were successfully engineered to produce VHH. Using a plasmid expression system, *L. paracasei* was engineered to constitutively express secreted or cell wall-anchored VHH1 (referred to as anti-rotavirus proteins \[ARP1\] in the present work), a VHH antibody that targets the RRV strain of rhesus monkey rotavirus serotype G3 (RRV). The study showed that both VHH1-secreting lactobacilli and VHH1-anchored lactobacilli bound and neutralized rotavirus *in vitro* in a dose-dependent manner. Moreover, VHH1-anchored lactobacilli were able to survive and constitutively produce VHH1 antibodies *in situ* in the jejunum and ileum after being orally administered to both uninfected and RRV-infected mice. The results highlighted the better performance of VHH1-anchored lactobacilli in preventing rotavirus infection and rotavirus-associated diarrhea in a mouse pup model of rotavirus infection. The good prophylactic effect observed was probably due to the numerous anti-rotavirus VHH antibodies exposed on the bacterial surface; these likely increased affinity for the viral particles, enhanced their agglutination, and facilitated their subsequent clearance. The same study also showed that recombinant VHH1-anchored lactobacilli maintain their protective activity after they are lyophilized and reconstituted. They can therefore be stored in lyophilized format, eliminating the dependence on a cold chain for their preservation, with all the advantages this brings.

![Recombinant LAB that produce VHH against rotavirus. A recombinant *Lactobacillus paracasei* strain with ARP1, targeting rhesus-monkey rotavirus serotype G3, anchored to its cell wall. The expression cassette harboring the gene encoding ARP1 is fused to a cell wall-anchoring signal sequence and is stably integrated within the bacterial chromosome.](fmicb-09-03179-g003){#fig3}

In a later study, [@ref159] showed that increasing the specificity of anti-rotavirus VHH improves the prophylactic and therapeutic effects of orally administered recombinant lactobacilli. These authors generated different recombinant *L. paracasei* strains that produced anti-rotavirus VHH with different valency formats (monovalent and bivalent VHH) and specificity (monospecific and bispecific VHH) that recognized different epitopes of the viral particle and that cross-reacted with and cross-neutralized different rotavirus serotypes *in vitro* ([@ref159]; [@ref6]). These strains produced either: 1) cell wall-anchored monovalent, monospecific ARP1 (referred to as VHH1 in the original study) or anti-rotavirus protein 3 (ARP3), 2) bivalent, monospecific ARP1-ARP1, ARP3-ARP3, or 3) bivalent, bispecific ARP1-ARP3 proteins. Although all the strains producing anchored VHH bound to the RRV strain *in vitro*, the bispecific ARP1-ARP3 format returned the best results. In addition, the latter neutralized RRV *in vitro* and reduced the infection rate. This strain showed the greatest *in vivo* prophylactic effect after being orally administered in a mouse pup model of rotavirus infection. In addition, in therapeutic use, it most strongly reduced the prevalence, severity, and duration of diarrheal disease. The generation of recombinant lactobacilli producing multivalent and multispecific VHH against rotavirus might improve their prophylactic and therapeutic efficacy against a broad range of viral serotypes.

More recently, [@ref76] developed several expression cassettes that were cloned in tandem to allow the co-expression of ARP1 and ARP3 as either secreted or cell wall-anchored forms in *L. paracasei* BL23. Using these cassettes, they generated three recombinant strains: *L. paracasei* pAF1300 producing secreted ARP1 and anchored ARP3, *L. paracasei* pAF1400 producing anchored ARP1 and ARP3, and *L. paracasei* pAF1200 producing secreted ARP1 and ARP3. Those producing ARP1 and ARP3 in anchored form bound a broad range of human and simian rotavirus serotypes with great affinity. Secreted ARP1 produced by *L. paracasei* pAF1300 and *L. paracasei* pAF1200 and secreted ARP3 produced by *L. paracasei* pAF1200 bound to different human rotavirus serotypes and simian rotavirus RRV. Analysis of the mechanism of interaction between rotavirus and *L. paracasei* pAF1300 suggested that once the virus is captured by anchored ARP3, the bacterium produces secreted ARP1, which targets other rotavirus epitopes. This confirms the feasibility of engineering *Lactobacillus* to co-produce VHH with different specificities and cell locations, increasing the chances of neutralizing different rotavirus serotypes and reducing the chances of escape mutants appearing. Moreover, the simultaneous production of several VHH with different specificities in one engineered *Lactobacillus* would considerably reduce production costs compared to preparing cocktails of different recombinant lactobacilli, each producing different VHH.

The recombinant lactobacilli described in the above-mentioned studies relied on plasmid expression systems for the production and delivery of anti-rotavirus VHH. These systems have been widely used to overproduce heterologous proteins in LAB, but they suffer drawbacks that hamper their use as delivery systems for the *in situ* production of therapeutic proteins in the GIT. For instance, expression plasmids show structural and segregational instability, and their maintenance in cells therefore requires a selection pressure, commonly resistance to antibiotics. The presence of antibiotic resistance genes in therapeutic recombinant lactobacilli, however, is undesirable since antibiotics would be needed to select VHH-producing strains in the intestine. In addition, they would increase the risk of antibiotic resistance genes being horizontally transferred to other, perhaps pathogenic, GIT bacteria.

Given the above, different approaches have been proposed to maintain heterologous genes in recombinant LAB. A feasible alternative is the use of food-grade expression vectors with selection markers other than antibiotics that provide new phenotypes (e.g., immunity to bacteriocins, utilization of rare sugars, etc.) or complement specific mutations that restore impaired functions (e.g., complementation of auxotrophic mutants depending on threonine, thymidine, alanine, lactose, etc.) ([@ref109]). But in any case, it is necessary to maintain a selective pressure in the GIT, which can be avoided by the chromosomal integration of the heterologous genes. [@ref137] developed a universal integrative expression system that allows the stable integration of expression cassettes for the production of scFv and VHH in the chromosome of *Lactobacillus*. This system is based on an ingenious genome editing technology, developed by [@ref136], that involves the site-specific integration of heterologous genes into the LAB chromosome, plus a purification system that -- once the vector is integrated into the chromosome -- leads to the elimination of all non-food-grade deoxyribonucleic acid, including the antibiotic selection genes. This system allowed the generation of different food-grade recombinant *L. paracasei* strains that stably produce VHH against rotavirus ([@ref137]). The recombinant *L. paracasei* EM233 strain, which stably produces cell wall-anchored ARP1 (Figure [3](#fig3){ref-type="fig"}), was shown to effectively bind rotavirus *in vitro*, and importantly, the integrated gene encoding APR1 VHH antibody was stable with no need for any selective pressure. After its oral administration, the recombinant *L. paracasei* strain producing anchored ARP1 showed prophylactic efficacy, reducing the duration and severity of diarrhea in a mouse model of rotavirus infection. More recently, *L. rhamnosus* GG was genetically engineered using this system to stably produce cell wall-anchored ARP1 antibody against rotavirus ([@ref8]). *L. rhamnosus* GG is a well-known probiotic strain that, in addition to having intrinsic anti-rotavirus activity ([@ref116]; [@ref75]), helps reinforce the intestinal barrier, triggers the innate and adaptive immune responses ([@ref179]), and transiently colonizes the intestine ([@ref7]). It is therefore an ideal vehicle for the production of VHH against rotavirus in the GIT mucosa. [@ref8] tested the capacity of several *L. rhamnosus* GG strains to display anchored ARP1 on their surfaces for which they used the plasmid-based expression system described above ([@ref137]). Although all these strains produced ARP1, only one, a naturally occurring exopolysaccharide-deficient mutant strain named *L. rhamnosus* GG (UT), efficiently produced anchored ARP1. Genomic analysis suggested that two genes (*welE* and *welF*) belonging to the exopolysaccharide (EPS) cluster were inactive in this strain, which impaired the production of cell-bound EPS. The EPS deficiency allowed the appearance of the anchored ARP1; in all the other strains tested the thick layer of EPS masked it. *L. rhamnosus* GG (UT) was further genetically engineered to produce ARP1 anchored to the cell wall through the use of the above-described integrative-expression system ([@ref137]). This strain, known as *L. rhamnosus* GG EM233, bounded rotavirus particles and seemed to confer a protective effect *in vivo*; when it was orally administered to mice before they were infected with rotavirus, the prevalence, duration, and severity of diarrhea were reduced compared to the control group ([@ref8]).

Thus, the oral administration of engineered lactobacilli that either secrete VHH or display cell wall-anchored VHH (with single or multiple valencies and specificities) may be a way of preventing or treating rotavirus infection and its associated diarrhea. The site-specific integration expression technology used in the above studies represents an important advance in the genetic manipulation of LAB for the generation of food-grade, live recombinant bacteria that produce prophylactic and therapeutic VHH *in situ* in the GIT.

Concluding Remarks and Future Perspectives {#sec18}
==========================================

Over the last decade, LAB have emerged as powerful oral delivery vectors for the *in situ* production of VHH at the GIT mucosa where they may act as therapeutic agents or provide passive protection against different gastrointestinal diseases. Specific LAB strains have been genetically modified to either secrete VHH or produce them anchored to their surfaces. This has been achieved using expression systems based on replicative plasmids, which require a selection pressure such as the presence of antibiotic resistance genes for their maintenance in bacteria ([@ref158], [@ref159]; [@ref198]; [@ref76]; [@ref12]) or by using other genetic tools that allow the integration of VHH-encoding genes into the bacterial chromosome. This provides stability to the integrated gene without the need for a selection pressure system ([@ref137]; [@ref8]). In the near future, other powerful chromosome editing technologies, such as those based on the CRISPR/Cas systems ([@ref84]), might also be used to generate recombinant LAB that stably produce VHH against diseases of the GIT. At the time of writing, only *L. lactis* ([@ref198]), *L. paracasei* ([@ref158], [@ref159]; [@ref137]; [@ref76]; [@ref12]), and *L. rhamnosus* ([@ref8]) have been engineered to produce VHH for treating or preventing GIT disease. Many LAB strains have been described as possessing probiotic characteristics of benefit against IBD ([@ref169]), and against the bacteria ([@ref69]; [@ref118]; [@ref139]) and viruses ([@ref75]) that cause gastrointestinal infections. Some of them even show anti-tumoral properties against colorectal cancer ([@ref10]). Based on their intrinsic benefits, specific probiotic LAB strains could be selected and genetically modified to produce therapeutic or prophylactic VHH. This would result in a synergistic effect against the target disease. So far, recombinant LAB that produce VHH have been directed to prevent or treat IBD ([@ref198]) and infections caused by *C. difficile* ([@ref12]) and rotavirus ([@ref158], [@ref159]; [@ref137]; [@ref76]; [@ref8]). Given the great potential of VHH as therapeutic and prophylactic agents, many other LAB might be engineered to produce VHH targeting other diseases of the GIT, such as infections caused by pathogenic bacteria (e.g., *C. jejuni*, *H. pylori*, ETEC, STEC, *Salmonella*, etc.), viruses (e.g., norovirus), fungi (e.g., *C. albicans*), and intestinal parasites and to provide relief from food allergies and intolerances, inflammatory diseases, and even gastrointestinal cancers. They might also be produced to treat disease in other mucous membranes inhabited by LAB.
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